Abstract
A trial was conducted in a commercial feedlot in western Canada using fall-placed feedlot calves at moderate risk of bovine respiratory disease (BRD) to compare the efficacy of gamithromycin to tilmicosin for metaphylactic treatment of BRD. First-pull treatment rates for BRD were significantly lower (P=0.01) in calves in the gamithromycin group than in the tilmicosin group. There were no other significant differences in health or performance between the two groups. The 6.6 percentage point difference in treatment rates for BRD equated to a net advantage of $0.03 CAN/head for those calves given gamithromycin as a metaphylactic drug on arrival compared to metaphylactic treatment with tilmicosin. Drug cost and disease risk should be carefully evaluated in each feedlot and group of incoming cattle to determine the most cost-effective metaphylaxis protocol.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
